GSK, Theravance begin phase-III programme to develop next general treatment for COPD
Thursday, October 29, 2009 18:00 IST London
GlaxoSmithKline (GSK) and Theravance, Inc announced that the first patient has commenced treatment as part of the phase-III programme being undertaken to develop